CXCR4/YY1 inhibition impairs VEGF network and angiogenesis during malignancy
Open Access
- 26 July 2010
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 107 (32), 14484-14489
- https://doi.org/10.1073/pnas.1008256107
Abstract
Tumor growth requires neoangiogenesis. VEGF is the most potent proangiogenic factor. Dysregulation of hypoxia-inducible factor (HIF) or cytokine stimuli such as those involving the chemokine receptor 4/stromal-derived cell factor 1 (CXCR4/SDF-1) axis are the major cause of ectopic overexpression of VEGF in tumors. Although the CXCR4/SDF-1 pathway is well characterized, the transcription factors executing the effector function of this signaling are poorly understood. The multifunctional Yin Yang 1 (YY1) protein is highly expressed in different types of cancers and may regulate some cancer-related genes. The network involving CXCR4/YY1 and neoangiogenesis could play a major role in cancer progression. In this study we have shown that YY1 forms an active complex with HIF-1α at VEGF gene promoters and increases VEGF transcription and expression observed by RT-PCR, ELISA, and Western blot using two different antibodies against VEGFB. Long-term treatment with T22 peptide (a CXCR4/SDF-1 inhibitor) and YY1 silencing can reduce in vivo systemic neoangiogenesis (P < 0.01 and P < 0.05 vs. control, respectively) during metastasis. Moreover, using an in vitro angiogenesis assay, we observed that YY1 silencing led to a 60% reduction in branches (P < 0.01) and tube length (P < 0.02) and a 75% reduction in tube area (P < 0.001) compared with control cells. A similar reduction was observed using T22 peptide. We demonstrated that T22 peptide determines YY1 cytoplasmic accumulation by reducing its phosphorylation via down-regulation of AKT, identifying a crosstalk mechanism involving CXCR4/YY1. Thus, YY1 may represent a crucial molecular target for antiangiogenic therapy during cancer progression.Keywords
This publication has 26 references indexed in Scilit:
- Targeting angiogenesis: progress with anti-VEGF treatment with large moleculesNature Reviews Clinical Oncology, 2009
- PTEN suppression of YY1 induces HIF-2 activity in von hippel lindau null renal cell carcinomaCancer Biology & Therapy, 2009
- Adverse effects of anticancer agents that target the VEGF pathwayNature Reviews Clinical Oncology, 2009
- A critical analysis of current in vitro and in vivo angiogenesis assaysInternational Journal of Experimental Pathology, 2009
- Transcription factor YY1: structure, function, and therapeutic implications in cancer biologyOncogene, 2005
- Yin Yang 1 Is a Negative Regulator of p53Cell, 2004
- Tumorigenesis and the angiogenic switchNature Reviews Cancer, 2003
- Nitric Oxide Inhibits the Transcription Repressor Yin-Yang 1 Binding Activity at the Silencer Region of the Fas Promoter: A Pivotal Role for Nitric Oxide in the Up-Regulation of Fas Gene Expression in Human Tumor CellsThe Journal of Immunology, 2001
- Characterization of the Transcriptional Regulator YY1Published by Elsevier BV ,1997
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisCell, 1996